Pyrazolo[3,4- d ]pyrimidine derivatives as VEGFR-2 and EGFR T790M dual inhibitors: design, docking, ADMET, synthesis and anticancer evaluations

January 1, 2026RSC AdvancesOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

To design and evaluate pyrazolo[3,4-d]pyrimidine derivatives as dual inhibitors of VEGFR-2 and EGFR T790M.
Designed novel derivatives based on scaffold.
Synthesized compounds through chemical reactions.
Conducted docking studies to assess binding affinity.
Evaluated anti-cancer activity in laboratory settings.
Assessed ADMET properties for drug-like characteristics.
Identified several potent dual inhibitors of VEGFR-2 and EGFR T790M.
Demonstrated effective binding in docking studies.
Showed promising anti-cancer activity compared to existing treatments.

Novel pyrazolo[3,4-d]pyrimidine derivatives inhibit EGFR T790M and VEGFR-2, suggesting potential in cancer treatment.

Novel pyrazolo[3,4- d ]pyrimidine derivatives have been designed, synthesized and examined as inhibitors of both EGFR T790M and VEGFR-2.

No takes yet. Share an insight, caveat, or question.

Aziz et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share